Cow's milk allergy A H0st MD DSc SECTION OF PAEDIATRICS, 22 OCTOBER 1996 Reproducible adverse reactions to cow's milk (CM) were first described more than 2360 years ago by Hippocrates, who is said to have observed that CM can cause urticaria and gastric upsetl. About 500 years later a case of milk allergy was described by Galen2. In the first years of this century, reports on adverse reactions to CM were published in the German literature3. In these early reports adverse reactions to CM were described as 'idiosyncrasy' to CM. In Scandinavia, Wernstedt from Sweden was the first to propose the term 'allergy' to supposing a changed reactivity to CM4. The American paediatrician, Talbot, described in 1916, the relation between 'idiosyncrasy' to CM and anaphylaxis to CM5. These reactions were reported to occur after ingestion of CM. In 1938 allergic reaction due to inhalation of cow's milk protein was described in a Danish dairy worker6. Cow's milk allergy was considered an infrequent disease, but since the 1950s an increasing frequency of this disease has been noted, possibly caused by a decrease in breast-feeding and a more frequent use of CMbased infant formula feeding7'8. During the last decades cow s milk allergy has become the most common food allergy in early childhood, and much attention has been paid to this disease, as elucidated in extensive reviews3 '7-14 However, much controversy still exists, probably because of a lack of agreement on standard terminology and lack of reliable diagnostic tests3. DEFINITION 
AND DIAGNOSTIC CRITERIA
The term, cow s milk allergy (CMA), is commonly used for immune-mediated reactions, while non immune-mediated reactions are classified as cow's milk intolerance (CMI). Like food allergy in general, CMA can be divided into IgEmediated, type I, and non IgE-mediated reactions, mainly type III (immune-complexes) and type IV (cell-mediated)'5.
Most studies on 'milk allergy' have not investigated the immunological basis of the clinical symptoms. Differentiation between CMA and CMI is not possible solely based on clinical symptoms, and no single laboratory test is diagnostic of CMA or CMI. Therefore, the diagnosis of CMA or CMI still has to be based on strict, well-defined food elimination and challenge procedures including double-blind placebocontrolled food challenge (DBPCFC) in children older than 1-2 years16. In young infants, open-controlled challenges have been shown to be reliable when performed under professional observation in a hospital setting'7. It is beyond the scope of this paper to deal with adverse reactions to milk due to a lack of the enzyme lactase. According to the new classification of the European Academy of Allergy and Clinical Immunology (EAACI) Subcommittee on Adverse Reactions to Foodsi5 reproducible adverse reactions to cow's milk proteins can be classified as CMA, i.e. immunemediated reactions (IgE-mediated and non IgE-mediated reactions) or CMI, i.e. non immune-mediated ('undefined', but non pharmacological and non enzymatic reactions). In order to avoid overdiagnosis the following diagnostic criteria should be fulfilled as a minimum:
(1) Definite disappearance of symptoms after each of two dietary eliminations of cow's milk and cow's milk products.
(2) Recurrence of identical symptoms after one challenge.
(3) Exclusion of lactose intolerance and coincidental infection (especially suspected in the case of monosymptomatic gastrointestinal symptoms).
In young infants these diagnostic criteria will usually be sufficient provided that challenge procedures are performed under professional observation in a hospital setting3. In solely breast-fed infants, elimination and challenge procedures should be performed via regulation of the mothers' intake of cow's milk. A well-defined standardized challenge schedule should be followed, including a description of the time intervals between increases in the amounts of cow's milk and the total amount of cow's milk before reaction3. In older children and in adults DBPCFC will often be necessary in order to exclude psychological or casual reactions'6-'8. However, in patients with delayed reactions DBPCFC will hardly be practicable. Therefore, a negative DBPCFC should always be followed by an opencontrolled challenge including normal intake of the food protein in question. For practical purposes the challenge recommendations given by Niggemann et al.19 are useful. varying estimates of the incidence from 1.8% to 7.5%21-27 have been reported, mainly reflecting differences in diagnostic criteria, in study design, different compositions of the materials, and maybe also geographical differences. In prospective longitudinal studies of unselected newborns the primary materials of infants with symptoms suggestive of CMA/CMI have varied between 5% and 15% of infants3. However, in infants suspected of CMA/CMI the diagnosis was only proven in about 1/3 when controlled elimination/ challenge was used, resulting in a 'true incidence' of CMA/ CMI in infancy of about 20/o-5% in developed countries ( Table 1 ). In two of the prospective longitudinal studies an association between the early introduction of cow's milk based formula and the development of CMA/CMI was documented21,26
In exclusively breast-fed infants the one-year incidence of CMA/CMI was found to be about 0.5% in two studies23 '26 These data confirm the findings by O'Keefe from 192028 that breast-fed infants may react to cow's milk protein ingested by the mother and transferred to the infant via the breast milk.
CLINICAL FEATURES
A broad spectrum of symptoms in children may be caused by CMA/CMI ( infants with CMA/CMI have more than one symptom and the majority (more than 70%) have symptoms from more than one organ system3. In exclusively breast-fed infants with CMA/CMI the symptomatology is similar to that seen in other infants with milk allergy, although severe atopic eczema seems to be a predominant symptom3. TREATMENT Milk-free diet The basic treatment of CMA/CMI is a complete avoidance of CM and CM products. Documented hypoallergenic formula is the only suitable diet for infants up to 6 months of age. After the introduction of solid foods after 4-6 months of age it is important to avoid milk proteins in commercially available foods, which may contain small quantities of milk proteins not listed on the labels, even in non-dairy products34 and specialist dietitians are often needed to ensure correct milk-free diets and adequate nutrition. Soy formulas cannot be generally recommended because adverse reactions to soy have been reported to occur in about 17% to 47% of children sensitive to cow's milk proteins (reviewed in Ref. 3) .
Goat's milk should not be recommended as a milk substitute to patients with CMA/CMI because most of the proteins of goat's milk (and also sheep's milk) share identity with those of cow's milk, resulting in cross-reactivity (reviewed in Ref. 3) .
'Normal' processing procedures such as pasteurization, spray draying, and evaporation do not eliminate but only reduce the antigenicity and allergenicity of milk proteins. Consequently such products should not be recommended for treatment of CMA/CMI.
In conclusion only documented hypoallergenic formulae should be used in infants with CMA/CMI. The extensively hydrolysed formulae (eHF) have been found to be substantially less antigenic and allergenic than partially hydrolysed formulae (pHF) in patients with CMA, although some individuals highly sensitized to cow's milk protein may react against residual quantities of cow's milk protein even in eHF, confirming the fact that none of the 'hypoallergenic' formulae are 'non-allergenic' 35 . It has been recommended that a hypoallergenic formula should fulfil the criterion of 90% clinical tolerance (with 95% confidence limits) in infants with proven CMA3536. Before use, a skin prick test with a fresh sample of the recommended ready-to-feed formula should be done in order to evaluate the allergenicity, followed by an opencontrolled challenge with the chosen formula if the skin prick test is positive. In children with reactions against even eHF, an amino acid-derived elemental formula, should be used37.
Because of a favourable prognosis of CMA/CMI it is very important to avoid over-treatment and an unnecessarily long-lasting milk-free diet. Therefore, controlled re-challenges are recommended at intervals of about 6-12 months in early childhood, and above 3 years of age at intervals of 1-2 years.
PROGNOSIS
The prognosis of CMA/CMI has recently been re-viewed3'38. The main results are shown in Table 3 .
The prognosis of CMA/CMI is good with a remission rate of about 450/o-55% at one year, 600/o-75% at 2 years and 850/o-90% at 3 years3. With increasing age a lower proportion, about 1/3 of still intolerant children, will develop tolerance to CM milk3'38. Infants with CMA (IgEmediated reactions to cow's milk protein) have a significantly lower rate of recovery than infants with non IgE-mediated reactions3'38. Generally the prognosis for non IgE-mediated reactions, e.g. gastrointestinal reactions, enteropathy, enterocolitis and colitis, is excellent with total recovery within 1-2 years on a milk-free diet.
Development of adverse reactions to other foods occur very often in infants with CMA/CMI, mostly against egg, soy, peanut, citrus, fish and cereals (reviewed in Ref. 3) . Widely varying frequencies of associated food intolerances probably reflect differences in eating habits, and particularly the age at which certain foods are introduced. Compared to infants with non IgE-mediated reactions to cow's milk protein, those with IgE-mediated reactions develop adverse reactions to other foods, and especially to egg, significantly more often3.
Development of allergy to environmental inhalant allergens has been reported in about 50% of such children by 3 years and in 80% before the age of puberty (reviewed in Refs 3 and 38) .
In conclusion the overall prognosis of CMA/CMI in infancy is good with a remission rate of about 850/o-90%. However, an early increased IgE-response to cow's milk protein is associated with an increased risk of persisting In studies on CMA/CMI increased frequencies of atopic predisposition among first-degree relatives have been reported with estimates between 41% and 80O3. In one study double parental atopic heredity was found in 23% versus 3% in the background population'7, and several studies have shown that genetic factors are of great importance for the development of IgE-mediated reac-tions39. Infants with an increased risk for development of CMA/CMI seem to have a primary immunoregulatory defect4 which can be identified by elevated cord blood IgE, high levels of specific IgE, low numbers of T cells4l, disturbed T helper/T suppressor cells42'43 or delayed postnatal maturation of T cell competence4.
Cow's milk protein antigens/allergens have not been shown to be particularly predisposing to the expression of IgE-mediated or other immune-mediated clinical allergic reactions. Food allergy/intolerance (FA, FI) is principally a problem in infancy and early childhood. Most of the infants will develop FA/FI in the same order as that in which the foods have been introduced into the diet. In developed countries, cow's milk proteins are the first foreign proteins given to infants. All cow's milk proteins, more than 25, can act as allergens. Cow's milk contains 30-35 g/L of total protein, 24-28 g/L caseins (80%), and 5-7 g/L whey proteins (20%). Formation of specific IgG, IgA, IgM antibodies to cow's milk proteins is a normal physiological response and can be demonstrated in normal children (highest levels in infancy) as well as in adults (reviewed in Ref. 3). It can be concluded that cow's milk proteins are antigenic/immunogenic in humans. The humoral immune response due to systemic immunity to foods involving formation of IgG, IgA and IgM antibodies is usually harmless as well as formation of low levels of IgE antibodies, whereas high levels of IgE antibodies to foods are predictive of a present or later development of allergic disease45. T cell mediated reactions in the gut have been responses can be detected and measured in humans, as well as in animals. There is evidence that T cell mediated reactions in the small bowel mucosa can cause immune mediated damage and malabsorption. Lymphokine detecting assays and lymphoblast stimulation tests have indicated a pathogenetic role of T cell mediated reactions to individual cow's milk proteins (reviewed in Refs 3, 15) .
The allergenicity of cow's milk proteins may be altered by technologic processing and/or by digestion. Enzymatic digestion (hydrolysis) denatures the sequential epitopes, whereas low heat treatment (low pasteurization at 75°C for 15 s) only ensures the bacteriological quality of milk and does not cause any significant reduction of the antigenicity or the allergenicity. However, strong heat treatment (121°C for 20min) may destroy the allergenicity of the whey proteins (mainly the conformational epitopes) but only reduces that of caseins. In general heat treatment only reduces but does not eliminate the allergenicity of milk proteins. As regards antigenicity/allergenicity, no significant difference has been found in comparative studies between unhomogenized and pasteurized/ homogenized milk in children with CMA/CMI46. Based on determination of specific IgE to individual cow's milk proteins in patients with CMA, the major allergens in infancy seem to be bovine serum albumin, betalactoglobulin and bovine immunoglobulin, whereas in older children beta-lactoglobulin, caseins and alfalactalbumin may be more reactive. In general most patients react to two or more proteins3.
Exposure to cow's milk proteins may occur prenatally considering that high molecular milk proteins may cross the placenta, stimulate the fetal immune system, and elicit a specific IgE response in the fetus indicated by the demonstration of specific IgE antibodies to various allergens in cord blood (reviewed in Ref. 47) .
Postnatally infants are exposed to food proteins including cow's milk proteins via human milk, when the mothers are ingesting cow's milk or cow's milk products (reviewed in Ref. 48 ). Thus, the cow's milk protein, betalactoglobulin, can be detected in the breast milk of 95% of lactating women (0.9-150jug/L, median value 4.2pg/L) when consecutive continual testing of breast milk is done48.
However, after introduction of CM-based formula into the infants' diet, the antigenic load of cow's milk proteins may be appreciable (enormous) during the first year amounting to about 10-15g/day or about 3.6-5.5kg/year when considering that normal cow's milk formula contains about 15 g/L. Cow's milk proteins are absorbed from the gut and can be measured in the blood in quantities of micrograms per litre serum both in children and adults4950. Macromolecular absorption is increased in preterm infants documented in several reports, and active immune and in newborns, and has also been demonstrated in infants with CMA. Whether an increased macromolecular absorption is a part of an allergic constitution/heredity or is due to temporal mucosal damage is not clarified, and the relevance of an increased absorption for development of clinical disease is unclear3.
Previously only a few studies have reported specific IgE antibodies against cow's milk proteins by means of RAST analysis in 00/o-3.7% of unselected and atopic predisposed newborns (reviewed in Ref. 3) . Recently, specific IgE against individual cow's milk proteins was demonstrated by means of CRIE analysis in 76% of a selected group of infants with later development of CMA/CMI. By means of a very sensitive method, the Magic Lite SQ-system, specific IgE against individual cow's milk proteins has been detected in cord blood among 11% and 9% of newborns with and without atopic predisposition, respectively5l. These data indicate that prenatal formation of specific IgE may be more frequent than previously suggested and prenatal sensitization may play a role in the pathogenesis of food allergy. Other authors have shown specific T cell proliferative responses from fetal leucocytes to specific inhalant and ingestant allergens supporting the hypothesis of intrauterine sensitiza-tion52.
Breast-fed infants with CMA may react against the minute amounts of cow's milk protein in human milk, but convincing evidence of allergic sensitization due to these minute amounts has never been documented. Postnatal sensitization due to foods, also during exclusive breastfeeding, may rather be due to 'unknown breaks' in the dietary regimen, inhalation of food protein or contact with contaminated hands. Thus, one should consider that just 1 mL of ordinary cow's milk contains 35 mg of protein, equal to about 3mg of beta-lactoglobulin (or 3000,ig) corresponding to the amount provided by about 2 months nursing 1 Lmilk/day. Considering the low frequency of CMA/CMI, the very small amounts of cow's milk protein in breast milk may induce tolerance to cow's milk protein rather than allergic sensitization and development of allergic disease. In contrast a significant association between early neonatal exposure to cow's milk formula feeding and subsequent development of cow's milk protein allergy/ intolerance has been documented3'21'26.
AETIOLOGICAL HYPOTHESIS
The recent evidence of sensitization in utero to both ingestant and inhalant allergens indicate that intrauterine sensitization occurs more frequently than previously suggested. Prenatal senzitization may play a role in the pathogenesis of allergic disease. However, a weak intrauterine sensitization may be a normal phenomenon like the well known weak IgE-response postnatally in infants without allergic disease45. Neonatal exposure to a 'high dose' of foreign protein (inhalant or ingestant) allergens may be a condition of development of allergic disease, particularly in individuals with a marked atopic predisposition.
